<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004433</url>
  </required_header>
  <id_info>
    <org_study_id>199/13395</org_study_id>
    <secondary_id>MUSC-6130</secondary_id>
    <secondary_id>MUSC-FDR001111</secondary_id>
    <nct_id>NCT00004433</nct_id>
  </id_info>
  <brief_title>Randomized Study of Pergolide in Children With Tourette Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the presumed mechanism of action of low dose pergolide to act acutely through the&#xD;
      dopaminergic autoreceptor or postsynaptically at D2 sites in children 7 to 17 with tourette&#xD;
      syndrome (GTS).&#xD;
&#xD;
      II. Compare tolerability and safety of pergolide in these patients to standard neuroleptic&#xD;
      therapy via naturalist assessment after 3-6 months of treatment using matched historical&#xD;
      controls on neuroleptics.&#xD;
&#xD;
      III. Determine efficacy of pergolide for tic control in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is a three part study: part I is a randomized, double blind, fixed single dose study;&#xD;
      part II is a randomized, open label, stratified study; and part III is a randomized, double&#xD;
      blind, placebo controlled study.&#xD;
&#xD;
      Part I patients are randomized to receive oral pergolide at one of three dose levels or&#xD;
      placebo for 10 weeks. Part II patients are randomized to receive either low or high dose&#xD;
      pergolide for 4 weeks.&#xD;
&#xD;
      Part III patients are randomized to first receive either pergolide or placebo by oral fixed&#xD;
      doses twice daily followed by flexible clinically adjusted dosing for the next 3 weeks after&#xD;
      a 2-week placebo run-in. Patients then cross over to receive the other treatment after&#xD;
      another 2 weeks of placebo run-in. Total treatment duration is 16 weeks.&#xD;
&#xD;
      Patients are followed at 6 months.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1994</start_date>
  <completion_date>September 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>74</enrollment>
  <condition>Tourette Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pergolide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        DSM IV primary diagnosis of Tourette syndrome (GTS) Multiple Axis I and Axis II diagnoses&#xD;
        allowed&#xD;
&#xD;
        Tourette symptom severity great enough to warrant medication (CGI severity index at least&#xD;
        4)&#xD;
&#xD;
        No chronic motor tic disorder or transient tic disorder, anorexia nervosa, pervasive&#xD;
        developmental disorders, substance/alcohol abuse or dependence within the past year,&#xD;
        schizophrenia or any psychotic disorder&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        At least 4 weeks since prior neuroleptic therapy&#xD;
&#xD;
        At least 2 weeks since all other prior medications&#xD;
&#xD;
        No concurrent neuroleptic therapy or psychotropic therapy (i.e., antidepressant or&#xD;
        anticholinergic)&#xD;
&#xD;
        No concurrent medication that may alter or interact with pergolide&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Performance status: Outpatient status&#xD;
&#xD;
        Hematopoietic: Normal or clinically insignificant values&#xD;
&#xD;
        Hepatic: Normal or clinically insignificant values&#xD;
&#xD;
        Renal: Normal or clinically insignificant values&#xD;
&#xD;
        Cardiovascular: Normal electrocardiogram&#xD;
&#xD;
        Other: No serious or unstable medical illness (i.e., diabetes, seizure disorder); Must be&#xD;
        able to perform required measurements (i.e., no low I.Q.); Effective contraception required&#xD;
        by all fertile patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Floyd R. Sallee</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <reference>
    <citation>Griesemer DA. Pergolide in the management of Tourette syndrome. J Child Neurol. 1997 Sep;12(6):402-3. No abstract available.</citation>
    <PMID>9309526</PMID>
  </reference>
  <reference>
    <citation>Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord. 1997 May;12(3):402-7. doi: 10.1002/mds.870120320.</citation>
    <PMID>9159736</PMID>
  </reference>
  <verification_date>March 2000</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Tourette syndrome</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pergolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

